Dr. Nassif on Examining Gut Microbial Signatures in the Tumor Microenvironment
Elise Nassif, MD, discusses examining gut microbial signatures in the tumor microenvironment.
Dr. Nassif on the Efficacy of Early-Phase Clinical Trials in Soft Tissue Sarcoma
Elise Nassif, MD, discusses the efficacy of early-phase clinical trials in soft tissue sarcoma.
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
2 Clarke Drive Cranbury, NJ 08512